To further investigate the anticancer effect of ebractenoid F on CHI3L1, lung cancer cells were transfected with CHI3L1 siRNA and treated with ebractenoid F. The combined treatment with CHI3L1 siRNA and ebractenoid F significantly reduced the expression of migration proteins (MMP9 and MMP13) compared with the treatment with ebractenoid F or CHI3L1 siRNA alone, and the wound healing assay also showed similar results (Figure 6A–C). Here, CHI3L1 is linked to lung cancer.